Vial Initiates Phase 1b Asthma Study, Doses First Patient
Vial has dosed the first patient in a Phase 1b clinical study evaluating its bispecific antibody targeting IL-13 and TSLP in individuals with asthma. The antibody is designed for potential twice-yearly administration.
Vial has commenced its Phase 1b clinical trial, administering its novel bispecific antibody to the first patient diagnosed with asthma. This investigational therapy is engineered to target two key cytokines, interleukin-13 (IL-13) and thymic stromal lymphopoietin (TSLP), which are implicated in Type 2 inflammatory pathways.
The study aims to assess the safety, tolerability, and pharmacokinetic profile of the antibody in an asthma patient population. Prior Phase 1a data from studies involving healthy volunteers indicated that the drug's pharmacokinetics could support a dosing regimen of twice-yearly (every six months).
This bispecific antibody is designed to provide broad, deep, and durable control of Type 2-driven diseases with a single half-life extended molecule. Its development targets conditions such as asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps.
Results from this trial are expected to provide further insights into the antibody's mechanism of action and its potential utility in managing severe Type 2 inflammatory conditions.